Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. EuroMap Study Group

Am J Perinatol. 1999;16(7):321-6. doi: 10.1055/s-2007-993879.

Abstract

We studied the association between acetaminophen exposure during pregnancy and the prevalence of congenital abnormalities and fetal growth. Our study included 123 women who had received a prescription of acetaminophen during pregnancy and/or 30 days before conception and 13,329 controls who did not receive any prescription at all. We found more malformations among those who received a prescription with an odds ratio of 2.3 (95% CI 1.0-5.4), but the type of malformations did not indicate a causal link. When restricting the study to first time pregnancies, we identified 58 women who received a prescription of acetaminophen during pregnancy and 30 days before conception and 7472 controls. We found no excess risk of malformation [OR = 0.7 (95% CI 0.1-5.5)], and no evidence that acetaminophen should influence fetal growth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Acetaminophen / adverse effects
  • Acetaminophen / therapeutic use*
  • Adolescent
  • Adult
  • Cohort Studies
  • Confidence Intervals
  • Databases as Topic
  • Denmark
  • Drug Prescriptions
  • Embryonic and Fetal Development / drug effects*
  • Female
  • Gestational Age
  • Humans
  • Maternal Exposure
  • Medical Record Linkage
  • Middle Aged
  • Odds Ratio
  • Parity
  • Pregnancy
  • Pregnancy Outcome*
  • Prevalence
  • Registries
  • Risk Factors

Substances

  • Acetaminophen